Of the 2,700+ recently funded biopharma companies, we identified 9 of the top teams using our Management Mosaic algorithm. From clinical trials tech to anti-aging drugs, proven founders and teams are innovating in new sectors.
The funding will help Waltz Health hire new employees and invest in product development. Here are the top-line bullets you need to know.
As care delivery shifts out of the hospital and into the home, these startups are driving home health innovation.
This news comes on the heels of its Series I round. The funding will help DNAnexus support product development and international growth. Here are the top-line bullets you need to know.
This report uses the CB Insights MVP Technology Framework to rank tech market planning decisions and give an adoption playbook for the clinical trials domain.
From precision medicine to genetic screening, here’s how Illumina is being unbundled.
Investment Thesis Map
We mined Amazon's acquisitions, investments, and partnerships to discern the company's strategic priorities in healthcare.
Investment Thesis Map
We mined Johnson & Johnson’s acquisitions, investments, and partnerships to discern the company's strategic priorities.
With the acquisition, LabCorp plans to enhance its liquid biopsy and NGS-based genomic profiling capabilities. Here are the top-line bullets you need to know.
The pandemic has forced us to reimagine all aspects of healthcare delivery. Discover what’s changed across telehealth, digital therapeutics, medical devices, and more.
The pandemic has exposed challenges in the pharmaceutical industry, from drug discovery to clinical trials to supply chain. Here’s how Apple, Microsoft, Google, and Amazon are addressing them and working to establish permanent places for themselves in the space through product launches, partnerships, M&A deals, and more.
The Series F round brings Benchling's total funding to $412M. Here are the top-line bullets you need to know.
Owkin has raised $254.1M in funding to date. Here are the top-line bullets you need to know.
Funding to psychedelics startups is on the rise. We discuss the sector’s market drivers, emerging themes, and key implications.
Here’s a sample of our digital health and healthcare research on the sector’s investment and funding trends, business models, tech solutions, and more.
The Series C funding helps TrialSpark reach a $1B valuation. Here are the top-line bullets you need to know.
Lifebit's total funding now stands at $70.5M. Here are the top-line bullets you need to know.
Using CB Insights’ Business Relationships data, we map out and analyze the growing number of business relationships between digital therapeutics startups and payers, providers, and pharmaceutical companies.
CRISPR. What is it? And why is the scientific community so fascinated by the potential applications of this gene-editing technology? Starting with its definition, we explain how this technology harnesses an ancient bacteria-based defense system — and how it will impact the world around us today.
From drug discovery to predictive analytics, here’s how emerging tech companies are disrupting the CRO model.
Big tech is coming for pharma. We analyze Amazon, Microsoft, Apple, and Google’s strategies and priorities across the pharmaceutical value chain.
Digital therapeutics are a growing focus within the digital health ecosystem, as funding, clinical validation, and product reimbursement gain momentum. We analyze the accelerating adoption of digital therapeutics and how they can improve patient outcomes.
Exscientia plans to advance its pipeline of AI-designed drugs into clinical testing. Here are the top line bullets you need to know.